HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Bennett, B. L. Search for Related Content PubMed PubMed Citation Articles by Bennett, B. L.

c-Jun N-terminal kinase-dependent mechanisms in respiratory disease

Experimental Therapeutics–Inflammation, Celgene, San Diego, CA, USA.

CORRESPONDENCE: B. L. Bennett, Celgene, Experimental Therapeutics–Inflammation, 4550 Towne Centre Court, San Diego, CA 92121, USA. Fax: 1 8585528716. E-mail: bbennett{at}celgene.com

Keywords: c-Jun N-terminal kinase, inflammation, kinases, pharmacotherapy, signal transduction

Received: January 26, 2006
Accepted March 25, 2006

Respiratory diseases pose a multifaceted dilemma. Although the symptoms and pathology are obvious and provide multiple opportunities for therapeutic investigation, at the same time, the molecular complexities and prioritisation are overwhelming.

Even within a disease such as asthma, the number of inducers, cell types, secondary mediators, chemical changes, immune responses and tissue modifications is remarkable. One means of therapeutically targeting this complexity is to identify individual factors responsible for regulating multiple disease processes.

The mitogen-activated protein kinase family integrates multiple diverse stimuli, and, in turn, initiates a cell response by phosphorylating and thereby modulating the activity of many target proteins. The c-Jun N-terminal kinase is a critical regulator of pro-inflammatory genes, tissue remodelling and apoptosis, and, therefore, represents an attractive target for novel therapies.

Pre-clinical and clinical investigation into the efficacy of c-Jun N-terminal kinase inhibitors has been ongoing since the late 1990s. Over the course of this work, hypotheses have shifted as to the role of c-Jun N-terminal kinase in the many processes that promote allergic, inflammatory, obstructive and fibrotic diseases of the lung. Inhibition of c-Jun N-terminal kinase may indeed provide a means of suppressing more pathological mechanisms in respiratory disease than first suspected.

This article has been cited by other articles:

				H. D. C. Francescato, R. S. Costa, F. B. Junior, and T. M. Coimbra Effect of JNK inhibition on cisplatin-induced renal damage Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2138 - 2148. [Abstract] [Full Text] [PDF]